AEON Biopharma, Inc. (AEON) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, AEON Biopharma reported revenue of $0. Net income was -$39.2M, or -$3.95 per diluted share. Operating activities generated -$17.3M of cash, leaving -$17.3M of free cash flow. At fiscal year end, AEON Biopharma held $5.6M in total assets against $60.6M in total liabilities, including $3.0M of cash and equivalents.
Open the full interactive AEON Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
AEON Biopharma Key Stats
| Share Price | $0.23 |
|---|---|
| Market Cap | $11.6M |
| 52-Week Range | $0.19 – $1.40 |
| Shares Outstanding | 50.5 million (basic, 2026 Q2) |
AEON Biopharma Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Goods Sold | $0 | $0 | — | — | — |
| Gross Profit | $0 | $0 | — | — | — |
| Operating Income | -$1.9M | -$3.3M | -$86,000 | $73.0M | -$12.8M |
| Pre-Tax Income | $8.2M | $10.9M | -$36.6M | $42.0M | -$39.2M |
| Income Tax | — | $883,329 | $0 | $0 | $0 |
| Net Income | $8.2M | $10.0M | -$36.6M | $42.0M | -$39.2M |
| Diluted EPS | $18.72 | $20.88 | — | $72.93 | -$3.95 |
AEON Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.5M | -$37.1M | -$11.8M | -$1.2M |
| Diluted EPS | -$0.39 | -$3.74 | -$0.29 | -$0.02 |
AEON Biopharma Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $497,412 | — | $5.2M | $13,000 | $3.0M |
| Current Assets | $835,224 | $109,196 | $6.2M | $1.6M | $3.4M |
| Total Assets | $276.9M | $279.5M | $6.8M | $3.1M | $5.6M |
| Current Liabilities | $834,585 | $3.9M | $13.0M | $14.1M | $6.9M |
| Total Long-Term Debt | — | — | — | $15.0M | $34.6M |
| Total Liabilities | $17.9M | $10.4M | $159.9M | $31.7M | $60.6M |
| Shareholders' Equity | -$16.9M | -$9.4M | -$153.0M | -$28.6M | -$55.0M |
AEON Biopharma Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$1.5M | -$981,428 | -$47.8M | -$20.3M | -$17.3M |
| Cash From Investing | -$276.0M | $401,925 | — | — | -$4,000 |
| Cash From Financing | $278.0M | $150,000 | $14.0M | $15.1M | $20.3M |
| Free Cash Flow | — | — | -$48.1M | — | -$17.3M |
Figures from AEON Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full AEON Biopharma financials page for every line item.
AEON Biopharma Company Profile
| Ticker | AEON |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Aliso Viejo, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001837607 |
Frequently Asked Questions
What was AEON Biopharma's revenue in fiscal 2025?
AEON Biopharma (AEON) reported revenue of $0 for fiscal 2025.
What is AEON Biopharma's annual revenue history?
AEON Biopharma's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was AEON Biopharma's net income in fiscal 2025?
AEON Biopharma reported net income of -$39.2M for fiscal 2025.
What was AEON Biopharma's earnings per share (EPS) in fiscal 2025?
AEON Biopharma's diluted EPS was -$3.95 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did AEON Biopharma generate in fiscal 2025?
AEON Biopharma generated -$17.3M of free cash flow in fiscal 2025.
What was AEON Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), AEON Biopharma reported revenue of $0.
How much debt does AEON Biopharma have?
AEON Biopharma reported $34.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of AEON Biopharma are outstanding?
AEON Biopharma reported a weighted average of 50.5 million basic shares outstanding in 2026 Q2.
What is AEON Biopharma's market cap?
Based on its latest closing price, AEON Biopharma (AEON) has a market capitalization of about $11.6M.
When does AEON Biopharma's fiscal year end?
AEON Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is AEON Biopharma headquartered?
AEON Biopharma lists its business address in Aliso Viejo, California in its SEC filings.